TIZANIDINE HYDROCHLORIDE

Post-LOE

tizanidine hydrochloride

ANI Pharmaceuticals

ANDAORALTABLET

Approved

Apr 2003

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

TIZANIDINE HYDROCHLORIDE (tizanidine hydrochloride) by ANI Pharmaceuticals is alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Approved for spasticity in adults. First approved in 2003.

Drug data last refreshed 18h ago

Mechanism of Action

alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Indications (1)

spasticity in adults

Company

Worked on TIZANIDINE HYDROCHLORIDE at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.